Source Data Figure 1 .xlsx

<b>e</b>, Cell viability of human osteoarthritis (OA) chondrocytes assessed using the alamar blue assay at 1 d, 3 d, 5 d, and 7 d after BNTA treatment (n = 14 for each group; 1 d, nonparametric test; 3 d, 5 d, and 7 d, one-way ANOVA). <b>f</b>, Quantification of mRNA levels for collagen type II alpha 1 chain (<i>COL2A1</i>), aggrecan<i> </i>(<i>ACAN</i>), proteoglycan 4 (<i>PRG4</i>), and SRY-box 9 (<i>SOX9</i>) in human OA chondrocytes treated with BNTA for 6 h. Fold changes relative to vehicle control are shown (n = 6 for each group; <i>COL2A1</i>, <i>ACAN</i>, <i>SOX9</i>, one-way ANOVA; <i>PRG4</i>, nonparametric test; three independent experiments). <b>g</b>, The mRNA levels of <i>Col2a1</i>, <i>Acan</i>, <i>Prg4</i>, and <i>Sox9</i> in interleukin 1 beta ( IL1β, 10 ng ml^-1)-induced rat OA chondrocytes treated with BNTA for 6 h (n = 6 for each group; <i>Col2a1</i>, one-way ANOVA; <i>Acan</i>, <i>Prg4</i>, and <i>Sox9</i>, nonparametric test; three independent experiments).<b> h,</b> The proteins levels of SOX9 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in human OA chondrocytes treated with vehicle or BNTA (0.1 μM) for 2d. <b>i,</b> The proteins levels of COL2A1, SOX9, and GAPDH were detected using western blotting assay in IL1β (10 ng ml^-1)-induced rat OA chondrocytes treated with or without BNTA (0.1 μM) for 2d. All data are shown as the mean ± standard deviation (s. d.). *<i>P</i> &lt; 0.05, **<i>P</i> &lt; 0.01, ***<i>P</i> &lt; 0.001.